Tumor Biology

, Volume 32, Issue 3, pp 451–459 | Cite as

Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers

  • Riitta Koivisto-Korander
  • Ralf Butzow
  • Anna-Maija Koivisto
  • Arto Leminen
Research Article


Uterine sarcomas are rare and aggressive gynecologic malignancies. In this immunohistochemical (IHC) study, expression of Ki-67, p53, CD10, CD44, desmin, smooth muscle actin, estrogen receptor α (ERα), androgen receptor (AR), progesterone receptor A (PRA), and c-kit and their influence on survival in cases of uterine carcinosarcoma (CS), leiomyosarcoma (LMS), and endometrial stromal sarcoma (ESS) were evaluated. Medical records were reviewed and data collected concerning all uterine sarcomas treated during a 12-year period at Helsinki University Central Hospital. There was sufficient histological material for IHC analysis and slide review in 67 cases. Survival analysis was performed using the Kaplan–Meier method, and median survival times with 95% confidence intervals are given. Survival in cases of LMS was statistically significantly affected by the expression of p53, ERα, and PRA. Striking differences in expression of IHC markers when comparing results with those in earlier studies were the absence of AR immunoreactivity in all uterine sarcomas and low incidence of c-kit (15%; in endometrial stromal sarcoma). None of the markers was statistically significantly associated with survival of ESS and CS patients. The expression of p53, ERα, and PRA in uterine LMS may give prognostic information concerning the behavior of the disease. Hormonal therapy could be recommended as a treatment option in cases of hormone receptor-positive LMS.


Uterine sarcoma Immunohistochemistry Tumor markers ERα PRA 


Conflicts of interest



  1. 1.
    Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956–1992: incidence, survival and mortality. Eur J Cancer. 1997;33(6):907–11.PubMedCrossRefGoogle Scholar
  2. 2.
    McMeekin DS. Sarcoma of the uterus. In: DiSaia G, editor. Clinical gynecologic oncology. 7th ed. Philadelphia: Mosby Elsevier; 2007. p. 185–200.Google Scholar
  3. 3.
    McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer. 2002;12(6):687–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC; 2003.Google Scholar
  5. 5.
    Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol. 2004;93(1):204–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Kokawa K, Nishiyama K, Ikeuchi M, Ihara Y, Akamatsu N, Enomoto T, et al. Clinical outcomes of uterine sarcomas: results from 14 years worth of experience in the Kinki district in Japan (1990–2003). Int J Gynecol Cancer. 2006;16(3):1358–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Denschlag D, Masoud I, Stanimir G, Gilbert L. Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol. 2007;33(1):91–5.PubMedGoogle Scholar
  8. 8.
    Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990–2001. Gynecol Oncol. 2008;111(1):74–81.PubMedCrossRefGoogle Scholar
  9. 9.
    Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54(3):355–64.PubMedCrossRefGoogle Scholar
  10. 10.
    Wolfson AH, Wolfson DJ, Sittler SY, Breton L, Markoe AM, Schwade JG, et al. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol. 1994;52(1):56–62.PubMedCrossRefGoogle Scholar
  11. 11.
    Yaziji H, Gown AM. Immunohistochemical analysis of gynecologic tumors. Int J Gynecol Pathol. 2001;20(1):64–78.PubMedCrossRefGoogle Scholar
  12. 12.
    McCluggage WG. Recent advances in immunohistochemistry in gynaecological pathology. Histopathology. 2002;40(4):309–26.PubMedCrossRefGoogle Scholar
  13. 13.
    Moinfar F, Azodi M, Tavassoli FA. Uterine sarcomas. Pathology. 2007;39(1):55–71.PubMedCrossRefGoogle Scholar
  14. 14.
    D’Angelo E, Spagnoli LG, Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Hum Pathol. 2009;40(11):1571–85.PubMedCrossRefGoogle Scholar
  15. 15.
    McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology. 2001;39(3):273–8.PubMedCrossRefGoogle Scholar
  16. 16.
    D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116(1):131–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Leitao MM, Soslow RA, Nonaka D, Olshen AB, Aghajanian C, Sabbatini P, et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer. 2004;15;101(6):1455–62.CrossRefGoogle Scholar
  18. 18.
    Akhan SE, Yavuz E, Tecer A, Iyibozkurt CA, Topuz S, Tuzlali S, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol. 2005;99(1):36–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Poncelet C, Walker F, Madelenat P, Bringuier AF, Scoazec JY, Feldmann G, et al. Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma. Hum Pathol. 2001;32(11):1190–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Chen L, Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol. 2008;27(3):326–32.PubMedCrossRefGoogle Scholar
  21. 21.
    Chu PG, Arber DA, Weiss LM, Chang KL. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol. 2001;14(5):465–71.PubMedCrossRefGoogle Scholar
  22. 22.
    Zhu XQ, Shi YF, Cheng XD, Zhao CL, Wu YZ. Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. Gynecol Oncol. 2004;92(1):71–9.PubMedCrossRefGoogle Scholar
  23. 23.
    International Federation of Gynecology and Obstetrics. Annual report of the results of treatment in gynaecological cancer. J Epidemiol Biostat. 2006;6.Google Scholar
  24. 24.
    Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol. 2001;32(9):984–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Mayerhofer K, Lozanov P, Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Acta Obstet Gynecol Scand. 2004;83(11):1085–8.PubMedGoogle Scholar
  26. 26.
    Kir G, Cetiner H, Karateke A, Gurbuz A, Bulbul D. Utility of MIB-1 and estrogen and progesterone receptor in distinguishing between endometrial stromal sarcomas and endometrial stromal nodules, highly cellular leiomyomas. Int J Gynecol Cancer. 2005;15(2):337–42.PubMedCrossRefGoogle Scholar
  27. 27.
    Popiolek D, Yee H, Levine P, Vamvakas E, Demopoulos RI. MIB1 as a possible predictor of recurrence in low-grade endometrial stromal sarcoma of the uterus. Gynecol Oncol. 2003;90(2):353–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Nordal RR, Kristensen GB, Stenwig AE, Trope CG, Nesland JM. Immunohistochemical analysis of p53 protein in uterine sarcomas. Gynecol Oncol. 1998;70(1):45–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Gokaslan H, Turkeri L, Kavak ZN, Eren F, Sismanoglu A, Ilvan S, et al. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. Gynecol Obstet Invest. 2005;59(1):36–40.PubMedCrossRefGoogle Scholar
  30. 30.
    Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol. 2003;91(3):504–12.PubMedCrossRefGoogle Scholar
  31. 31.
    Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998;11(8):728–34.PubMedGoogle Scholar
  32. 32.
    Oliva E, Young RH, Amin MB, Clement PB. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol. 2002;26(4):403–12.PubMedCrossRefGoogle Scholar
  33. 33.
    Rushing RS, Shajahan S, Chendil D, Wilder JL, Pulliam J, Lee EY, et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol Oncol. 2003;91(1):9–14.PubMedCrossRefGoogle Scholar
  34. 34.
    Winter 3rd WE, Seidman JD, Krivak TC, Chauhan S, Carlson JW, Rose GS, et al. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus. Gynecol Oncol. 2003;91(1):3–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, et al. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol. 2010;117(2):248–54.PubMedCrossRefGoogle Scholar
  36. 36.
    Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 2010;46(7):1271–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Kahara N, Ozaki T, Doi T, Nishida K, Kawai A, Shibahara M, et al. CD44 expression in soft tissue sarcomas. Virchows Arch. 2000;436(6):574–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Ansink AC, Cross PA, Scorer P, de Barros LA, Monaghan JM. The hormonal receptor status of uterine carcinosarcomas (mixed Mullerian tumours): an immunohistochemical study. J Clin Pathol. 1997;50(4):328–31.PubMedCrossRefGoogle Scholar
  39. 39.
    Ioffe YJ, Li AJ, Walsh CS, Karlan BY, Leuchter R, Forscher C, et al. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol. 2009;115(3):466–71.PubMedCrossRefGoogle Scholar
  40. 40.
    Wade K, Quinn MA, Hammond I, Williams K, Cauchi M. Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol Oncol. 1990;39(3):364–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Huang GS, Chiu LG, Gebb JS, Gunter MJ, Sukumvanich P, Goldberg GL, et al. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol. 2007;107(3):513–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Huang GS, Arend RC, Li M, Gunter MJ, Chiu LG, Horwitz SB, et al. Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma. Am J Obstet Gynecol. 2009;200(4):457.e1–5.CrossRefGoogle Scholar
  43. 43.
    Lassus H, Butzow R. The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer. Br J Cancer. 2007;21;96(10):1621–2. author reply 1623–4.CrossRefGoogle Scholar
  44. 44.
    Kim SH, Kim JW, Kim YT, Kim JH, Yoon BS, Ryu HS. Prognostic factors and expression of p53 and mdm-2 in uterine sarcomas. Int J Gynaecol Obstet. 2006;95(3):272–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Blom R, Guerrieri C, Stal O, Malmstrom H, Simonsen E. Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol. 1998;68(1):54–61.PubMedCrossRefGoogle Scholar
  46. 46.
    Anderson SE, Nonaka D, Chuai S, Olshen AB, Chi D, Sabbatini P, et al. P53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas. Int J Gynecol Cancer. 2006;16(2):849–53.PubMedCrossRefGoogle Scholar
  47. 47.
    Geisler JP, Geisler HE, Miller GA, Wiemann MC, Zhou Z, Crabtree W. MIB-1 in endometrial carcinoma: prognostic significance with 5-year follow-up. Gynecol Oncol. 1999;75(3):432–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Iwasa Y, Haga H, Konishi I, Kobashi Y, Higuchi K, Katsuyama E, et al. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients. Cancer. 1998;1;82(3):512–9.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2010

Authors and Affiliations

  • Riitta Koivisto-Korander
    • 1
  • Ralf Butzow
    • 2
  • Anna-Maija Koivisto
    • 3
  • Arto Leminen
    • 1
  1. 1.Department of Obstetrics and GynecologyUniversity of HelsinkiHelsinkiFinland
  2. 2.Department of Pathology and HUSLABUniversity of HelsinkiHelsinkiFinland
  3. 3.School of Public HealthUniversity of TampereTampereFinland

Personalised recommendations